Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Pine Labs IPO Opens Amidst Declining Grey Market Premium, Sees Modest Day 1 Subscription

Tech

|

Updated on 07 Nov 2025, 06:30 am

Whalesbook Logo

Reviewed By

Simar Singh | Whalesbook News Team

Short Description:

The initial public offering (IPO) of fintech firm Pine Labs, aiming to raise Rs 3,900 crore, opened on November 7. On its first day, the issue saw a 7% subscription. Retail investors showed better interest, subscribing 30% of their portion, while Non-Institutional Investors booked 3%. Qualified Institutional Buyers have not yet made significant bids. The Grey Market Premium (GMP) has fallen significantly, currently trading around 2-5% from earlier highs, indicating caution. The IPO closes on November 11, with shares set to list on November 14.
Pine Labs IPO Opens Amidst Declining Grey Market Premium, Sees Modest Day 1 Subscription

▶

Detailed Coverage:

The Rs 3,900 crore Initial Public Offering (IPO) from Pine Labs, a prominent fintech company, commenced on November 7. The issue comprises a fresh issue of Rs 2,080 crore and an offer-for-sale of equity shares by existing investors including Peak XV Partners, Macritchie Investments, Madison India, Mastercard, and PayPal. The IPO aims to raise capital and provide liquidity to these early investors. Pine Labs operates in digital payment solutions, point-of-sale terminals, and gift cards for merchants and consumers.

The IPO price band is set between Rs 210 to Rs 221 per share, valuing the company at approximately Rs 25,377 crore at the higher end. Investors can apply for a minimum of 67 shares.

Initial subscription figures for the first day show the overall issue subscribed at 7%. Retail investor portions were subscribed 30%, while Non-Institutional Investors (NII) booked 3%. Qualified Institutional Buyers (QIBs) have not yet placed substantial bids.

Compounding market sentiment concerns, the Grey Market Premium (GMP) for Pine Labs has seen a sharp decline. Unlisted shares were trading with a GMP of just over 2 percent according to Investorgain, a notable drop from rates of 5-16 percent seen earlier this month. This falling GMP suggests reduced investor enthusiasm ahead of the listing.

Analysts offer mixed views. HDFC Securities highlights Pine Labs' strong position in digitizing commerce. However, Angel One assigned a 'Neutral' rating, citing valuation discomfort due to the company being loss-making and trading at a premium to listed peers on an EV/EBITDA basis, despite a positive sector outlook.

Impact: This IPO introduces a significant fintech player to the public markets. Investor demand, reflected in subscription levels and GMP, will be closely watched. The valuation concerns raised by analysts suggest potential volatility post-listing. The declining GMP indicates caution among market participants, which could impact initial trading performance. Rating: 6/10

Difficult terms explained: IPO (Initial Public Offering): The first time a private company offers its shares to the public to raise capital. Grey Market Premium (GMP): The price at which unlisted shares trade unofficially before they are listed on stock exchanges. A rising GMP usually indicates strong demand, while a falling GMP suggests waning interest. Fresh Issue: Shares issued by the company to raise new capital. The money goes directly to the company. Offer for Sale (OFS): Existing shareholders sell their shares to new investors. The money goes to the selling shareholders, not the company. Retail Investors: Individual investors who invest smaller amounts. Non-Institutional Investors (NII): High Net Worth Individuals (HNIs) and corporate bodies that invest larger sums than retail investors but less than QIBs. Qualified Institutional Buyers (QIB): Large institutional investors like mutual funds, FIIs, insurance companies, etc., who invest significant amounts. EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization. A valuation metric used to compare companies.


Environment Sector

European Union Agrees on 2040 Emissions Target With Carbon Credit Flexibility

European Union Agrees on 2040 Emissions Target With Carbon Credit Flexibility

European Union Agrees on 2040 Emissions Target With Carbon Credit Flexibility

European Union Agrees on 2040 Emissions Target With Carbon Credit Flexibility


Healthcare/Biotech Sector

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Eli Lilly's Mounjaro Becomes India's Top-Selling Drug by Value Amidst Surging Demand for Weight-Loss Therapies

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib

Alembic Pharmaceuticals Secures USFDA Final Approval for Generic Blood Cancer Drug Dasatinib